Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Biological Effects of Polysaccharides from Bovistella utriformis as Cytotoxic, Antioxidant, and Antihyperglycemic Agents: In Vitro and In Vivo Studies
Indexado
WoS WOS:001452754300001
Scopus SCOPUS_ID:105001344356
DOI 10.3390/PHARMACEUTICS17030335
Año 2025
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Background/Objectives: This study explores the bioactive potential of Bovistella utriformis biomass and its polysaccharides (PsBu) through comprehensive biochemical and bioactivity analyses, focusing on their antioxidant, cytotoxic, and antihyperglycemic properties. Methods: Elemental analysis determined the biomass's chemical composition. Antioxidant activity was assessed using ABTS and DPPH assays. Monosaccharide composition was analyzed via gas chromatography-mass spectrometry (GC-MS). In vitro cytotoxicity assays were conducted on cancer and normal cell lines to determine IC50 values and selectivity indices (SI). Zebrafish embryo toxicity was evaluated for teratogenic effects, and an in vivo antihyperglycemic study was performed in diabetic rat models. Results: The biomass exhibited high carbon content (around 41%) and nitrogen levels, with a balanced C/N ratio nearing 5. Protein content exceeded 50%, alongside significant carbohydrate, fiber, and ash levels. Antioxidant assays revealed inhibition rates of approximately 89% (ABTS) and 64% (DPPH). GC-MS analysis identified glucose as the predominant sugar (>80%), followed by galactose and mannose. Additionally, HPLC detected a photoprotective compound, potentially a mycosporin-like amino acid. Cytotoxicity assays demonstrated PsBu's selective activity against colon, lung, and melanoma cancer cell lines (IC50: 100-500 mu g<middle dot>mL(-1)), while effects on normal cell lines were lower (IC50 > 1300 mu g<middle dot>mL(-1) for HaCaT, >2500 mu g<middle dot>mL(-1) for HGF-1), with SI values approaching 27, supporting PsBu's potential as a targeted anticancer agent. Zebrafish embryo assays yielded LC50 values ranging from 1.4 to 1.8 mg<middle dot>mL(-1). In vivo, PsBu reduced fasting blood glucose levels in hyperglycemic rats (approximately 210 mg<middle dot>dL(-1) vs. 230 mg<middle dot>dL(-1) in controls) and preserved pancreatic beta-cell integrity (around 80% vs. 65% in controls). Conclusions: These findings suggest that B. utriformis biomass and PsBu exhibit strong antioxidant activity, selective cytotoxicity against cancer cells, and antihyperglycemic potential, making them promising candidates for further biomedical applications.

Revista



Revista ISSN
Pharmaceutics 1999-4923

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Pharmacology & Pharmacy
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Maaloul, Aya - Univ Malaga - España
Universidad de Málaga - España
2 Manriquez, Claudia Perez - Universidad de Concepción - Chile
3 Decara, Juan - Hosp Reg Univ Malaga - España
Hospital Regional Universitario Carlos Haya - España
4 Mari-Beffa, Manuel - Univ Malaga - España
Biomed Res Inst Malaga - España
Platform Nanomed IBIMA BIONAND Platform - España
Universidad de Málaga - España
Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina - España
5 alvarez-Torres, Daniel - Univ Malaga - España
Universidad de Málaga - España
6 Redoli, Sofia Latorre - Univ Malaga - España
Universidad de Málaga - España
7 Martinez-Albardonedo, Borja - Universidad de Magallanes - Chile
8 Araya-Rojas, Marisel - Universidad de Magallanes - Chile
9 FAJARDO-MORALES, VICTOR MANUEL Hombre Universidad de Magallanes - Chile
10 Diaz, Roberto T. Abdala - Univ Malaga - España
Universidad de Málaga - España

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
FEDER
gobierno de España
Federación Española de Enfermedades Raras
Instituto de Salud Carlos III
Andalusian Government
ISCIII
European Social Fund Plus
European Social Fund, "Investing in your future", Gobierno de Espana
National System of Health
NextGenerationEU and Andalusian Government
“Investing in your future”

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
This study was funded by the UMA18-FEDERJA-274 grant (Andalusian Government), PCM_00035 (NextGenerationEU and Andalusian Government) and group BIO 217 funds (Andalusian Government and FEDER). Funders had no role in the design or realization of this work. Juan Decara holds a "Miguel Servet" research contract from the National System of Health (CP21/00021), ISCIII cofunded by European Social Fund, "Investing in your future", Gobierno de Espana.
This study was funded by the UMA18-FEDERJA-274 grant (Andalusian Government), PCM_00035 (NextGenerationEU and Andalusian Government) and group BIO 217 funds (Andalusian Government and FEDER). Funders had no role in the design or realization of this work. Juan Decara holds a \u201CMiguel Servet\u201D research contract from the National System of Health (CP21/00021), ISCIII cofunded by European Social Fund, \u201CInvesting in your future\u201D, Gobierno de Espa\u00F1a.

Muestra la fuente de financiamiento declarada en la publicación.